Analysts See $-0.42 EPS for Kindred Biosciences, Inc. (KIN)

Kindred Biosciences, Inc. (NASDAQ:KIN) Logo
Investors sentiment increased to 2.24 in Q3 2018. Its up 0.24, from 2 in 2018Q2. It increased, as 7 investors sold Kindred Biosciences, Inc. shares while 14 reduced holdings. 18 funds opened positions while 29 raised stakes. 21.65 million shares or 9.04% more from 19.86 million shares in 2018Q2 were reported.
Blackrock has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 1.83M shares. Nj State Employees Deferred Compensation Plan reported 23,000 shares. Tower Research Cap (Trc) owns 62 shares or 0% of their US portfolio. 18,940 were reported by Raymond James. Renaissance Technology Limited Liability Co reported 0.02% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). Moreover, Parallax Volatility Advisers Lp has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 25 shares. Royal National Bank & Trust Of Canada owns 5,993 shares for 0% of their portfolio. Goldman Sachs Inc has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Moreover, Dorsey Wright Assocs has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). Aqr Capital Mngmt Limited Liability Com holds 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN) for 10,260 shares. Bnp Paribas Arbitrage owns 1,327 shares or 0% of their US portfolio. Rhumbline Advisers stated it has 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Citadel Advisors Ltd Co owns 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 26,740 shares. Amundi Pioneer Asset Mngmt reported 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). D E Shaw And Comm has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN).

Since September 4, 2018, it had 1 insider buy, and 6 insider sales for $4.34 million activity. $7.05M worth of stock was bought by Park West Asset Management LLC on Friday, January 18. Townsend Raymond also sold $39,958 worth of Kindred Biosciences, Inc. (NASDAQ:KIN) shares.

Analysts expect Kindred Biosciences, Inc. (NASDAQ:KIN) to report $-0.42 EPS on March, 7.They anticipate $0.07 EPS change or 20.00 % from last quarter’s $-0.35 EPS. After having $-0.39 EPS previously, Kindred Biosciences, Inc.’s analysts see 7.69 % EPS growth. The stock increased 3.41% or $0.35 during the last trading session, reaching $10.61. About 143,122 shares traded. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 63.18% since February 12, 2018 and is uptrending. It has outperformed by 63.18% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $410.21 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

More notable recent Kindred Biosciences, Inc. (NASDAQ:KIN) news were published by: which released: “Kindred Biosciences (KIN) Announces FDA Approval of Mirataz for Cat Weigh Loss –” on May 07, 2018, also with their article: “This Peninsula company’s new drug is the cat’s meow — the FDA says so – San Francisco Business Times” published on May 07, 2018, published: “Kindred Biosciences up 4% on positive KIND-510a data – Seeking Alpha” on January 14, 2019. More interesting news about Kindred Biosciences, Inc. (NASDAQ:KIN) were released by: and their article: “RADISSON HOSPITALITY AB (PUBL): NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING – GlobeNewswire” published on November 15, 2018 as well as‘s news article titled: “3 Stocks to Buy and Hold for the Next 50 Years – The Motley Fool” with publication date: April 16, 2018.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart